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Objective: To determine the antipsychotic efficacy and extrapyramidal safety of intramuscular (IM) olanzapine
and IM haloperidol during the first 24 hours of treatment of acute schizophrenia.
Method: Patients (n = 311) with acute schizophrenia were randomly allocated (2:2:1) to receive IM olanzapine
(10.0 mg, n = 131), IM haloperidol (7.5 mg, n = 126), or IM placebo (n = 54).
Results: After the first injection, IM olanzapine was comparable to IM haloperidol and superior to IM placebo
for reducing mean change scores from baseline on the Brief Psychiatric Rating Scale (BRPS) Positive at 2
hours (–2.9 olanzapine, –2.7 haloperidol, and –1.5 placebo) and 24 hours (–2.8 olanzapine, –3.2 haloperidol,
and –1.3 placebo); the BPRS Total at 2 hours (–14.2 olanzapine,–13.1 haloperidol, and –7.1 placebo) and 24
hours (–12.8 olanzapine, –12.9 haloperidol, and –6.2 placebo); and the Clinical Global Impressions (CGI) scale
at 24 hours (–0.5 olanzapine, –0.5 haloperidol, and –0.1 placebo). Patients treated with IM olanzapine had sig-
nificantly fewer incidences of treatment-emergent parkinsonism (4.3% olanzapine vs 13.3% haloperidol, P =
0.036), but not akathisia (1.1% olanzapine vs 6.5% haloperidol, P = 0.065), than did patients treated with IM
haloperidol; they also required significantly less anticholinergic treatment (4.6% olanzapine vs 20.6%
haloperidol, P < 0.001). Mean extrapyramidal symptoms (EPS) safety scores improved significantly from base-
line during IM olanzapine treatment, compared with a general worsening during IM haloperidol treatment
(Simpson–Angus Scale total score mean change: –0.61 olanzapine vs 0.70 haloperidol; P < 0.001; Barnes
Akathisia Scale global score mean change:–0.27 olanzapine vs 0.01 haloperidol; P < 0.05).
Conclusion: IM olanzapine was comparable to IM haloperidol for reducing the symptoms of acute schizophre-
nia during the first 24 hours of treatment, the efficacy of both being evident within 2 hours after the first injec-
tion. In general, more EPS were observed during treatment with IM haloperidol than with IM olanzapine.
(Can J Psychiatry 2003;48:716–721)
Information on funding and support and author affiliations appears at the end of the article.
Clinical Implications
 Intramuscular (IM) olanzapine 10.0 mg has efficacy for reducing agitation that compares to, but is more rapid than,
IM haloperidol 7.5 mg. It is also efficacious for reducing positive symptoms and general psychopathology in patients
with acute schizophrenia.
 IM olanzapine has a more favourable overall extrapyramidal symptoms (EPS) safety profile than IM haloperidol,
which could enhance compliance with antipsychotic maintenance therapy.
 The rapid alleviation of agitation, early reduction of positive symptoms, and relatively low propensity for EPS dur -
ing treatment with IM olanzapine could improve the prognosis of some patients with schizophrenia.
Key Words: schizophrenia, agitation, antipsychotic agent, intramuscular, olanzapine,
haloperidol, positive symptoms, extrapyramidal safety measures, extrapyramidal symptoms,
EPS
Acutely agitated patients with schizophrenia experiencegreat personal distress and may present a danger to them-
selves or others (1). Such patients are frequently treated with
intramuscular (IM) antipsychotic agents or benzodiazepines,
or both, when rapid alleviation of agitation is necessary (2,3).
IM typical antipsychotics may also reduce both positive
symptoms and general psychopathology (4); however, they
can cause extrapyramidal symptoms (EPS), which in turn re-
duces compliance with antipsychotic maintenance therapy
and increases the risk of relapse (5,6). Also, IM typical
antipsychotics must often be coadministered with
benzodiazapines (7), which further increases the risk of
adverse events.
We recently reported that IM olanzapine 10.0 mg had efficacy
comparable to IM haloperidol 7.5 mg for reducing acute agita-
tion in patients with schizophrenia and that IM olanzapine had
a more rapid onset of action (8). Further, treatment with IM
olanzapine was not associated with acute dystonia, whereas
7.1% of patients treated with IM haloperidol experienced this
distressing adverse event. We now report additional data from
the same study on the antipsychotic efficacy and extra-
pyramidal safety of IM olanzapine and IM haloperidol during
the first 24 hours of treatment of acute schizophrenia.
Methods
Patient Population
We recruited men and women aged 18 years and over who had
been diagnosed according to DSM-IV criteria with schizo-
phrenia, schizophreniform disorder, or schizoaffective disor-
der. All patients had a minimum total score of 14 on the
Positive and Negative Syndrome Scale–Excited Component
(PANSS–EC), which consists of the items “tension,”
“uncooperativeness,” “hostility,” “poor impulse control,” and
“excitement.” All patients also had a score of 4 or higher on at
least 1 item (1 to 7 scoring system for each item). Patients were
clinically agitated and appropriate candidates for IM treat-
ment, as assessed by the site investigator. We excluded preg-
nant or lactating women and patients with serious medical
illnesses, for whom pharmacotherapy posed a substantial clin-
ical risk or confounded diagnosis. The following treatments
were prohibited: 1) injectable depot antipsychotic or
injectable zuclopenthixol acetate 1 injection interval before
the first IM injection, 2) psychostimulants or reserpine 1 week
before the first IM injection, 3) benzodiazepines 4 hours
before the first IM injection, and 4) oral or rapid-acting IM
antipsychotic 2 hours before the first IM injection.
Study Design
The study was conducted between February 1999 and
November 1999 by 51 investigators in 13 countries (specifi-
cally, Australia, Austria, Belgium, Canada, the Czech Repub-
lic, France, Greece, Hungary, Italy, the Republic of South
Africa, Spain, the UK, and the US). Written informed consent
was obtained from all patients after study procedures were
fully explained to them.
The screening period (a minimum of 2 hours) included physi-
cal examinations and collection of standard histories and
baseline measurements; no antipsychotics or sedatives were
administered. Following screening, patients were randomly
allocated by the assignment of treatment kits to double-blind
treatment with IM olanzapine 10.0 mg, IM haloperidol 7.5
mg, or IM placebo (2:2:1 ratio; 1 to 3 injections over 24 hours,
with the second injection more than 2 hours after the first, and
the third injection more than 4 hours after the second, given on
the basis of clinical need). The randomization ratio limited
placebo exposure. IM haloperidol was chosen as a comparator
because it is the IM antipsychotic agent most frequently used
for treating acutely agitated schizophrenia patients (4,9).
One benzodiazepine dose (up to 20 mg diazepam equivalents)
was allowed 1 hour or more after the second IM injection of
the study drug, and a second dose was allowed 1 hour or more
after the third injection. Anticholinergic medications were
only permitted for the control of EPS adverse events occur-
ring during the study. Other concomitant medications with
primarily central nervous system activity were prohibited.
Assessments
Efficacy. The PANSS-derived Brief Psychiatric Rating Scale
(BPRS) Total score was completed at baseline and at 2 hours
and 24 hours after the first injection. Positive symptoms were
evaluated with the BPRS Positive subscale, and general
psychopathology was further evaluated with the Clinical
Global Impressions (CGI) scale (specifically, the Severity of
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Limitations
 It will be important to determine whether our results generalize to the more severely ill pa -
tients treated in routine clinical practice.
 It will be of interest to compare the EPS safety profile of IM olanzapine 10.0 mg with a lower
dosage of IM haloperidol (for example, 5.0 mg).
 We did not investigate potential synergies and interactions between IM olanzapine and other
drugs (for example, benzodiazepines) used in the treatment of acute schizophrenia.
Illness [CGI-S] scale at baseline and the Improvement of Ill-
ness [CGI-I] scale at 24 hours after the first injection).
Extrapyramidal Safety. The incidences of treatment-
emergent parkinsonism (that is, the proportion of patients
with a Simpson–Angus Scale total score of more than 3, out of
those with a total score 3 or less at baseline [10]) and
treatment-emergent akathisia (that is, the proportion of
patients with a Barnes Akathisia Scale global score [item 4] of
2 or more, out of those with a score less than 2 at baseline [11])
were evaluated for the 24-hour IM period. Mean changes on
these EPS scales were also derived from baseline to the
24-hour endpoint.
Statistical Methods
We evaluated between-group comparisons of mean baseline-
to-endpoint changes in psychotic symptoms, parkinsonism,
and akathisia during the IM period using an analysis of vari-
ance (ANOVA) model that included the terms for treatment
and the country. Categorical data were evaluated with
Fisher’s exact test. All hypothesis tests were performed with a
2-sided significance level of 0.05.
Results
Patient Characteristics
In all, 311 patients were randomized (IM olanzapine n = 131,
IM haloperidol n = 126, and IM placebo n = 54). Patient demo-
graphic and illness characteristics (Table 1) were comparable
across treatment groups, as were baseline efficacy and EPS
rating scale scores (Tables 2 and 3).
Patient Disposition
In all, 285 (91.6%) patients completed the 24-hour IM period
(IM olanzapine 93.1%, IM haloperidol 92.1%, and IM pla-
cebo 87.0%). Adverse events caused 5 patients to discontinue.
Of these, 3 (2.4%) received IM haloperidol and showed acute
dystonia, extrapyramidal syndrome, and neuroleptic malig-
nant syndrome, respectively. The remaining 2 (1.5%)
received IM olanzapine and showed anxiety and maculo-
papular rash, respectively. Significantly more patients given
IM placebo (9.3%) discontinued because of lack of efficacy,
compared with those treated with IM olanzapine (1.5%;
Fisher’s exact test, P = 0.023) or IM haloperidol (0%; Fisher’s
exact test, P = 0.002).
Mean Changes in Positive Symptoms and General
Psychopathology
IM olanzapine and IM haloperidol were comparable and were
both superior to IM placebo for reducing scores on the BPRS
Positive and Total at 2 hours after the first injection and on all
scales at 24 hours after the first injection (Table 2).
As previously reported, significantly more patients given IM
placebo (38.9%) received benzodiazepines during the study,
compared with patients receiving IM olanzapine (16.0%;
Fisher’s exact test, P = 0.002) or IM haloperidol (19.8%;
Fisher’s exact test, P = 0.009) (8). Mean daily benzodiazepine
dosages did not differ significantly among the groups (IM
olanzapine mean 3.8, SD 4.2 mg; IM haloperidol mean 3.5,
SD 2.8 mg; and IM placebo mean 3.1, SD 2.1 mg).
Categorical Incidences of Parkinsonism and Akathisia
Patients receiving IM olanzapine experienced significantly
fewer incidences of treatment-emergent parkinsonism (4.3%
with IM olanzapine vs 13.3% with IM haloperidol; Fisher’s
exact test, P = 0.036) but not akathisia (1.1% with IM
olanzapine vs 6.5% with IM haloperidol; Fisher’s exact test,
P = 0.065), compared with patients receiving IM haloperidol,
and no more incidences of either parkinsonism or akathisia
than patients given IM placebo (parkinsonism 3.1% and
akathisia 2.8%).
Mean Changes in EPS Measures
At 24 hours after the first injection, mean scores on EPS rating
scales were significantly reduced during IM olanzapine treat-
ment, compared with an increase during IM haloperidol treat-
ment (Simpson–Angus Scale t276 = 3.6, P < 0.001; Barnes
Akathisia Scale t276 = 3.1, P = 0.002) (Table 3). IM olanzapine
and IM placebo cohorts were comparable for both EPS
measures.
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Table 1 Baseline patient demographic and illness characteristics
Patient characteristic
Intramuscular olanzapine
(n = 131)
Intramuscular haloperidol
(n = 126)
Intramuscular placebo
(n = 54)
Total
(n = 311)
Sex, number (%)
Men 85 (64.9) 86 (68.3) 33 (61.1) 204 (65.6)
Women 46 (35.1) 40 (31.7) 21 (38.9) 107 (34.4)
Origin, number (%)
European 95 (72.5) 97 (77.0) 34 (63.0) 226 (72.7)
African 24 (18.3) 22 (17.5) 13 (24.1) 59 (19.0)
Asian, Latin American, other 12 (9.2) 7 (5.6) 7 (13.0) 26 (8.4)
Mean age, years (SD) 38.2 (12.2) 38.5 (11.1) 37.6 38.2
Mean age of illness onset, years (SD) 23.5 (8.9) 25.1 (8.3) 24.9 (8.0) 24.4 (8.5)
Concomitant Anticholinergic Use
As previously reported, significantly fewer patients treated
with IM olanzapine (4.6%; Fisher’s exact test, P < 0.001) or
given IM placebo (3.7%; Fisher’s exact test, P = 0.003)
received anticholinergic medication, compared with patients
receiving IM haloperidol (20.6%) (8). Mean daily anti-
cholinergic dosages were similar across all groups (IM
olanzapine mean 2.0, SD 1.1 mg; IM haloperidol mean 2.7,
SD 1.9 mg; and IM placebo mean 2.0, SD 0.0 mg).
Discussion
We recently reported that IM olanzapine 10.0 mg had efficacy
comparable to IM haloperidol 7.5 mg for reducing acute
agitation in patients with schizophrenia (8). IM olanzapine
had a more rapid onset of action, and no incidence of acute
dystonia was reported during IM olanzapine treatment (com-
pared with an incidence of 7.1% for IM haloperidol). These
additional data from the same study show that IM olanzapine
and IM haloperidol have comparable efficacy in reducing
positive symptoms and general psychopathology during the
first 24 hours after the first injection. IM olanzapine also dem-
onstrated a more favourable EPS safety profile than did IM
haloperidol, with no reports of acute dystonia and signifi-
cantly fewer reports of treatment-emergent parkinsonism.
Efficacy in reducing positive symptoms and general psycho-
pathology are important during the treatment of patients with
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Table 2 Mean changes in positive symptoms and general psychopathology
Measure Intramuscular therapy n Baseline mean (SD) Mean change (SD)
At 2 hoursa At 24 hoursb
BPRS Positive Olanzapine 129c 10.7 (3.8) –2.9 (3.3)d –2.8 (3.1)d
Haloperidol 125 10.7 (4.5) –2.7 (3.4)d –3.2 (3.5)d
Placebo 54 10.8 (4.9) –1.5 (2.1) –1.3 (2.7)
BPRS Total Olanzapine 129c 39.3 (8.9) –14.2 (11.1)d –12.8 (9.0)d
Haloperidol 125 38.3 (9.8) –13.1 (9.8)d –12.9 (8.9)d
Placebo 54 39.5 (10.3) –7.1 (7.4) –6.2 (9.0)
CGI-Ie Olanzapine 122 5.0 (0.8) — –0.5 (0.8)f
Haloperidol 121 4.9 (0.8) — –0.5 (0.8)f
Placebo 48 4.8 (0.8) — –0.1 (0.6)
BPRS = Brief Psychiatric Rating Scale; CGI-I = Clinical Global Impressions–Improvement of Illness; — = no data collected.
a 2-hour overall treatment effect from the main effects model with terms for treatment and country using raw data: BPRS Positive F2,288 = 4.1, P = 0.018; BPRS
Total F2,288 = 9.3, P < 0.001.
b 24-hour overall treatment effect from the main effects model with terms for treatment and country using raw data: BPRS Positive F2,295 = 6.4, P = 0.002;
BPRS Total F2,295 = 11.7, P < 0.001; CGI-I F2,278 = 6.2, P = 0.002.
cAt 2 hours, n = 122.
d
P < 0.001 vs intramuscular placebo.
eMeasured at baseline using the CGI-I scale; change measured at 24 hours only.
f
P < 0.05 vs intramuscular placebo.
Table 3 Mean changes in extrapyramidal safety measures
Measure Intramuscular therapy n
Baseline
mean (SD)
Mean change (SD)
at 24 hoursa
Simpson–Angus Scale Olanzapine 122 2.51 (3.92) –0.61 (2.26)b
Haloperidol 120 2.54 (3.74) 0.70 (3.54)
Placebo 47 3.02 (4.46) –1.19 (3.23)
Barnes Akathisia Scale (Global Assessment) Olanzapine 121 0.73 (0.96) –0.27 (0.73)c
Haloperidol 120 0.73 (0.97) 0.01 (0.77)
Placebo 48 0.85 (0.99) –0.08 (0.79)
a 24-hour overall treatment effect from the main effects model with terms for treatment and country using raw data: Simpson–Angus Scale F2,276 = 9.6,
P < 0.001; Barnes Akathisia Scale F2,276 = 4.8, P = 0.009.
b
P < 0.001 vs intramuscular haloperidol.
c
P < 0.05 vs intramuscular haloperidol.
acute schizophrenia, not only to reduce subjective distress but
also because these symptoms have been correlated with vio-
lence (12,13). In this study, IM olanzapine was comparable to
IM haloperidol for reducing positive symptom and general
psychopathology scores as early as 2 hours after an injection
(with the first measurement taken at 2 hours) and for at least
24 hours. Oral olanzapine has demonstrated superiority over
oral haloperidol in improving overall psychopathology (14).
Parkinsonism and akathisia can be extremely distressing, and
patients can be understandably reluctant to continue
antipsychotic maintenance therapy after experiencing these
adverse events (5). Medication noncompliance in general is
the leading cause of relapse in schizophrenia (6). The overall
favourable EPS safety profile of IM olanzapine could poten-
tially enhance patients’ adherence to antipsychotic mainte-
nance therapy, but this requires further research. The findings
of significantly less acute dystonia and treatment-emergent
parkinsonism and significantly improved scores on EPS rat-
ing scales during IM olanzapine treatment, compared with IM
haloperidol treatment, are consistent with oral olanzapine
clinical trial literature (14–16).
This study has some important limitations. First, the applica-
bility of our results to more severely ill patients treated in rou-
tine clinical practice needs to be determined, since ethical
considerations prevent their recruitment to clinical trials.
Nonetheless, we took care to include patients who were ill
enough for any effect of active treatment on their symptoms to
be evident but not so ill that they were unable to provide
informed consent or cooperate with the clinical trial require-
ments. The suitability of the enrolled patients is attested to by
their response to IM haloperidol, which is known to effec-
tively reduce symptoms of schizophrenia. Second, future
studies are needed to investigate a range of IM medication
dosages (for example, a lower dosage of IM haloperidol).
Third, we did not investigate potential synergies and inter-
actions between IM olanzapine and other drugs used for treat-
ing acute schizophrenia (for example, benzodiazepines).
Finally, further research is required to test the hypothesis that
the efficacy and EPS safety advantages of IM olanzapine can
reduce subjective distress and the risk of violence in patients
with schizophrenia, leading to enhanced compliance with
antipsychotic maintenance therapy and prevention of relapse.
In summary, IM olanzapine and IM haloperidol were compa-
rable in reducing the symptoms of acute schizophrenia during
the first 24 hours of treatment, their efficacy being evident
within 2 hours after the first injection. Generally more EPS
were observed during treatment with IM haloperidol than
with IM olanzapine. Overall, the data from this clinical trial
suggest that IM olanzapine is an efficacious, yet safer, alterna-
tive to IM haloperidol for the treatment of both acute agitation
and psychotic symptomatology in patients with schizophre-
nia. Further, because it has been suggested that early clinical
improvement predicts a more favourable eventual outcome
(17), the rapid alleviation of agitation and early reduction of
positive symptoms during treatment with IM olanzapine
could improve the prognosis of some patients with
schizophrenia.
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Résumé : Olanzapine intramusculaire et halopéridol intramusculaire dans la
schizophrénie aiguë : efficacité antipsychotique et innocuité extrapyramidale
durant les 24 premières heures de traitement
Objectif : Déterminer l’efficacité antipsychotique et l’innocuité extrapyramidale de l’olanzapine
intramusculaire (IM) et de l’halopéridol IM durant les 24 premières heures du traitement de la
schizophrénie aiguë.
Méthode : Les patients (n = 311) souffrant de schizophrénie ont été choisis au hasard (2:2:1) pour
recevoir de l’olanzapine IM (10,0 mg, n = 131), de l’halopéridol IM (7,5 mg, n = 126) ou un placebo
IM (n = 54).
Résultats : Après la première injection, l’olanzapine IM était comparable à l’halopéridol IM et
supérieure au placebo IM pour réduire le changement depuis le départ des scores moyens à l’échelle
abrégée de classement psychiatrique (BPRS) positif à 2 heures (–2,9 olanzapine, –2,7 halopéridol, et
–1,5 placebo) et 24 heures (–2,8 olanzapine, –3,2 halopéridol, et –1,3 placebo); le total du BPRS à 2
heures (–14,2 olanzapine, –13,1 halopéridol, et –7,1 placebo) et 24 heures (–12,8 olanzapine, –12,9
halopéridol, et –6,2 placebo); et à l’échelle Impression clinique globale (CGI) à 24 heures (–0,5
olanzapine, –0,5 halopéridol, et 0,1 placebo). Les patients traités à l’olanzapine IM avaient
significativement moins d’incidences de syndrome parkinsonien apparaissant avec le traitement
(4,3 % olanzapine c. 13,3 % halopéridol, P = 0,036), mais pas d’acathisie (1,1 % olanzapine c. 6,5 %
halopéridol, P = 0,065), que les patients traités à l’halopéridol IM et nécessitaient significativement
moins de traitement anticholinergique (4,6 % olanzapine c. 20,6 % halopéridol, P < 0,001). Les
scores moyens d’innocuité des symptômes extrapyramidaux (SEP) se sont améliorés
significativement depuis le départ durant le traitement à l’olanzapine IM, comparativement à une ag-
gravation générale durant le traitement à l’halopéridol IM (changement du score total moyen à
l’échelle Simpson–Angus : –0,61 olanzapine c. 0,70 halopéridol; P < 0,001; changement du score to-
tal moyen à l’échelle Barnes Akathisia : –0,27 olanzapine c. 0,01 halopéridol; P < 0,05).
Conclusion : L’olanzapine IM était comparable à l’halopéridol IM pour réduire les symptômes de la
schizophrénie aiguë durant les 24 premières heures du traitement, l’efficacité des deux médicaments
étant évidente moins de deux heures après la première injection. En général, plus de SEP ont été
observés durant le traitement à l’halopéridol IM qu’à l’olanzapine IM.
